Amivantamab (Rybrevant)

Immunotherapy

US Experimental EU Experimental ES med_spain_not_funded IV 5 Clinical Trials
EGFR MET

Description

Amivantamab is a bispecific monoclonal antibody that targets both EGFR and MET receptor proteins simultaneously. In colorectal cancer, it is used specifically for patients with KRAS/NRAS/BRAF wild-type tumors, where it is combined with standard chemotherapy regimens like FOLFIRI or mFOLFOX6. This dual-targeting approach allows amivantamab to block two key growth signaling pathways that drive tumor progression in these molecularly-defined CRC subsets.

Mechanism of Action

Amivantamab binds to both the epidermal growth factor receptor (EGFR) and the MET receptor tyrosine kinase, blocking their activation by growth factors. By simultaneously inhibiting these two pathways, it prevents tumor cells from using alternative signaling routes to escape single-agent EGFR blockade, a common resistance mechanism in colorectal cancer.

Molecular Targets

Side Effects

Infusion-related reactions Rash Nail toxicity Diarrhea Fatigue Peripheral edema Hypoalbuminemia Pulmonary embolism

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06750094 med_phase_prefix3
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
United States, Australia, Belgium, Brazil, China, France, Germany, Hong Kong, Hu
NCT06662786 med_phase_prefix3
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
United States, Belgium, Brazil, Canada, China, France, Germany, Hungary, India,
NCT05845450 med_phase_prefix2
Recruiting
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Italy
NCT05379595 med_phase_prefix1
Recruiting
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
United States, Belgium, Canada, China, Germany, Italy, Malaysia, Puerto Rico, So
NCT06855849 med_phase_prefix2
Not yet recruiting
An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatm
South Korea

Quick Info

Brand NameRybrevant
CategoryImmunotherapy
US StatusExperimental
EU Estado EMAExperimental
ES Acceso Españamed_spain_not_funded
AdministrationIV
Clinical Trials5
View Clinical Trials Back to Drug Glossary

Related Medications

Cetuximab
Immunotherapy
350 trials
Panitumumab
Immunotherapy
121 trials
Regorafenib
Targeted Therapy
107 trials
Fruquintinib
Targeted Therapy
55 trials
Erlotinib
Targeted Therapy
18 trials
Cabozantinib
Targeted Therapy
11 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.